Samplix® is always interested in supporting groundbreaking research. We have established collaborations with leading researchers within the genomics space performing groundbreaking research. A few are mentioned below.


Samplix and Bioneer collaborate to tackle challenges in genomics.

Bioneer provides customized gene editing services including advanced quality control of gene edited cell models and will through their partnership with Samplix offer their customers access to the Xdrop technology.

 Learn more: Bioneer and CRISPR Editing Verification.

200527 Samplix Bioneer v4

Uppsala University & SciLifeLab

“We have had a long collaboration with the Samplix team. They have listened to our feedback, and we are glad to see how far this technology has come since the early days when we received the world’s first Xdrop in our lab”

- Dr. Adam Ameur, Uppsala University & SciLifeLab

Dr. Adam Ameur from Uppsala University and Science for Life Laboratory (SciLifeLab), Sweden has, among other applications, used the Xdrop® system for target enrichment and single molecule sequencing of the TP53 gene for phasing variants in DNA from leukemia patients. With the Xdrop® method, Dr. Ameur and his team successfully phased point mutations present in the leukemia cancer samples. To read more about the project, click below.

A Ameur

Photo credit: Uppsala University


Samplix has been awarded a grant from the European Commission’s prestigious Horizon 2020 SME program. From May 1st 2019 to May 1st 2021, the funding will accelerate the development of the Xdrop® technology by optimizing the process and products based on user feed-back. Samplix has engaged in interaction with users and the feedback has been used not only to develop the technology, but also to further improve the user experience. The grant allows Samplix to expand activities and move towards the aim of the grant “Improving DNA Analysis for Correct Healthcare – IMPACT”.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848497